BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) reported upbeat earnings for the first quarter on Wednesday.



The company posted quarterly earnings of 14 cents per share which beat the analyst consensus estimate of 5 cents per share. The company reported quarterly sales of $156.413 million which beat the analyst consensus estimate of $151.123 million.



BioCryst Pharma affirmed FY2026 sales guidance of $635.000 million-$660.000 million.



“We began 2026 with continued strong execution across our business, led by sustained growth of ORLADEYO and solid progress across our pipeline,” said Charlie Gayer, President and Chief Executive Officer of BioCryst. “ORLADEYO continues to grow because its differentiated oral profile and high level of attack control meet the needs of an increasing number of people living with hereditary angioedema. At the same time, we remain on track with enrollment in our navenibart and BCX17725 pipeline programs. We are also pleased to partner again with Neopharmed Gentili for European rights to navenibart. This progress underscores our strategy to focus on rare diseases where we have deep expertise, execute efficiently, and allocate capital thoughtfully to drive sustainable value for patients and shareholders.”



BioCryst Pharma shares fell 1% to trade at $8.74 on Thursday.



These analysts made changes to their price targets on BioCryst Pharma following earnings announcement.



<ul>
<li>Wedbush analyst Laura Chico maintained BioCryst Pharma with an Outperform rating and lowered the price target from $22 to $21.</li>



<li>Citizens analyst Jonathan Wolleben maintained the stock with a Market Outperform and raised the price target from $25 to $28.</li>
</ul>



Considering buying BCRX stock? Here’s what analysts think:



<figure class="wp-block-image size-large is-resized"></figure>



Photo via Shutterstock

BCRX

LABU

SBIO

BioCryst Pharma (NASDAQ:BCRX) reported strong Q1 earnings, with earnings of 14 cents per share and sales of $156.413 million, both exceeding analyst expectations. The company reaffirmed its FY2026 sales guidance of $635-$660 million. Analysts revised their price targets, with Wedbush lowering it from $22 to $21, while Citizens raised it from $25 to $28. BioCryst shares fell 1% to $8.74 following the announcement.

benzinga_article

BioCryst Pharma

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

iShares Biotechnology ETF

Citizens Financial

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SR I

CITIZENS FINANCIAL GROUP INC 5% DEP SHS EA REP 1/40TH NON CUM SER E

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SER H

These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings